![[Functional and Stereotactic Neurosurgery]](/images/INRadhome8.JPG) ![[Cerebrovascular Surgery Center]](/images/VASChome8.JPG) |
Interventional
Neuroradiology ~ GDC
Coils
Endosaccular Coiling of Cerebral Aneurysms
Christopher M.
Putman,M.D., Frank Huang-Hellinger, M.D. Ph.D,
and Christopher Ogilvy, M.D. |
The
Interventional Neuroradiology service at Massachusetts General
Hospital
and the MGH Brain Aneurysm & AVM Center. |
Intracranial aneurysms constitute a significant public health problem
in the United States. Spontaneous rupture of cerebral aneurysms typically
results in subarachnoid hemorrhage and affects 10-30/100,000 patients/year.
As many as 10 % of patients die before reaching the hospital. Of those
who do reach the hospital, the greatest risk to life is aneurysm re-bleeding
although cerebral vasospasm makes a significant contribution to overall
morbidity and mortality. Considering that as many as 50% of subarachnoid
hemorrhage patients eventually die as a result of their hemorrhage
and an additional 25% suffer permanent neurological injury, any cerebral
aneurysm deserves a thorough evaluation for potential treatment.
The primary goal of treatment of cerebral
aneurysms is to prevent future rupture. What can we tell patients
about their risk of future rupture? The best available data suggest
that previously unruptured aneurysms carry a risk of hemorrhage
of about 1-2 %/year. If subdivided by size, the risk is probably
slightly lower for small aneurysms (< 1cm) and slightly higher for
large aneurysms (1-2.5cm). The presence of multiple aneurysms and
a family history of subarachnoid hemorrhage probably also raise
the risk of rupture. Once an aneurysm has ruptured, the chance of
re-hemorrhage dramatically increases. Of those patients who survive
an initial subarachnoid hemorrhage, approximately 20 % re-bleed
in the first 2 weeks and 35% over the first month if the aneurysm
is left untreated. After the first 30 days the risk falls back to
1-2 % per year.
Surgical clipping is the mainstay
of treatment of both ruptured and unruptured cerebral aneurysms.
In this approach, the affected artery must be exposed and the aneurysm
visualized directly. The surgeon can then carefully apply a metal
clip to the base of the aneurysm thereby blocking blood flow into
the aneurysm. Once the aneurysm is eliminated from the flow of blood
the risk of hemorrhage is eliminated. The advent of microneurosurgical
techniques and advancements in cerebrovascular surgery (temporary
clipping, neuroprotection, etc.) have extended the applicability
of aneurysm surgery and improved surgical outcomes. In spite of
these advancements, there remain aneurysms which are difficult to
clip even in the best of hands.
In 1991, Guglielmi detachable coil
(GDC) embolization was introduced as an alternative method for treating
selected aneurysm patients. The GDC system consists of a very soft
and flexible microcoiled paltinum wire with intrinsic helical memory
that is attached to a delivery mandrel. The coil is attached to
the mandrel by a special soldered joint and can be "detached" once
in the aneurysm by electrolysis. GDC embolization involves transarterial
delivery of these platinum coils into the lumen of the aneurysm
by way of a microcatheter placed into the aneurysm. The goal of
the treatment is prevent the flow of blood into the aneurysm sack
by filling the aneurysm with coils and thrombus. It has been shown
in animals that this approach leads to organization of the thrombus
in the aneurysm and with further healing to formation of a membrane
across the neck of the aneurysm. This completes exclusion of the
aneurysm from the flow of blood. Using the analogy of the surgical
treatment, the technique is in effect placing an endosacular "clip".
Theorectically, there are several
advantages of GDC over surgery. These procedures are performed under
general anesthesia in the neuroangiography suite utilizing the standard
transfemoral approaches used in diagnostic angiography. Potentially,
the treatment could be combined with the initial diagnositic cerebral
angiogram thereby reducing the period of risk of re-rupture. Because
the approach is transarterial, multiple aneurysms can be treated
during a single procedure, or GDC treatment could be combined with
treatment of co-morbid conditions such as vasospasm (intra-arterial
papaverine or angioplasty). Also, since there is no scarring of
the route of approach to the aneurysm as there is in the case of
surgery, staged or multiple procedures can be performed without
added difficultly. Finally, since the approach is endovascular,
the issues which make any particular location relatively straightforward
or more difficult are entirely different. Therefore, some locations
which are relatively difficult for surgery (basilar tip) are straightforward
for GDC. (Of course, the opposite is also true of other sites-e.g.
middle cerebral.)
Despite these potential advantages,
surgery remains the primary treatment modality for most aneurysms.
Surgical clipping has been successfully applied to intracranial
aneurysms for many years and the durability of the treatment has
been proven. This minimizes the need for post procedure angiographic
studies which are required for any patient treated with GDC. Surgery
also provides controlled access to areas of difficult anatomy and
allows for arterial reconstruction for aneurysms with complex shapes
and wide necks in which GDC could not be applied.
Massachusetts General Hospital was
one of the sites in the multicenter trial involving a total of some
1200 patients that ultimately achieved FDA approval for the GDC
technology. Since the beginning of the trial, we have developed
an increasing practice in GDC therapy here at the MGH such that
we are currently treating 20-30 aneurysms per year we this technique.
The results so far indicate that more than 80% of GDC-treated aneurysms
with a relatively narrow neck (arbitrarily defined as = 4 mm)
have been occluded permanently with morbidity and mortality rates
of approximately 5% and 2%, respectively. The major risks of the
procedure are aneurysm rupture, parent artery occlusion and thromboembolic
events either during or in the period immediately following the
procedure. Results of wide necked aneurysms are less satisfactory
with a 15% rate of complete occlusion and 85% rate of significant
partial occlusion (³70%) was achieved.
Since its inception GDC embolization
has evolved as a result of both clinical experience and the introduction
of improvements in the technology. We are now much better at selecting
aneurysms appropriate for treatment. Recently published work (Malisch
1997) confirms our experience that giant aneurysms are less likely
to have a completely successful outcome after GDC embolization.
Such aneurysms have a significant likelihood of coil compaction
into the aneurysm, causing a recurrence of the aneurysm lumen and,
more concerning, an alarmingly high hemorrhage rate after embolization
(33% of such patients in one small series with an average follow-up
interval of 3.5 years). We also now know that aneurysms that project
along the direction of blood flow in the parent artery (e.g., superiorly
directed basilar tip) are at increased risk for coil compaction
into the aneurysm. Finally, there is the suggestion from autopsy
data that thick-walled, calcified giant aneurysms are less likely
to undergo clot organization and ultimate exclusion of the aneurysm
from the circulation than is thought to be the case for small, thin
walled aneurysms. Certainly, we have the best results with small
aneurysms which also have small necks.
Technological advances in GDC technology
have also improved this method of treatment. Over the last several
years, the number of coil sizes has been increased, multi-dimensional
coils allowing safer initial coil placement have become available,
and more recently, much softer coils have been introduced. The manufacturing
process which forms the attachment of the platinum coil with the
stainless steel introducing wire has also been improved such that
this detachment zone dissolves much quicker during the electrolytic
process than previously. This improvement has dramatically reduced
the time needed to detach each coil from up to several hours to
almost always less than 10 minutes. Another significant technical
refinement has been in the area of microcatheters. We now have braided,
hydrophilically coated microcatheters which allow improved access
to many aneurysms thereby increasing our chances of obtaining a
complete aneurysm obliteration.
Our current approach is to consider
GDC treatment as a complement to the surgical treatment of cerebral
aneurysms. We consider using GDC in any patient in which surgery
may carry an increased risk. These typically include patients with
co-morbid medical conditions, with high Hunt and Hess Grades (³4),
or with increased intracranial pressure following SAH. Aneurysms
in which surgical exposure carries an unacceptable risk ( i.e. posteriorly
directed basilar tip aneurysms or paraclinoid aneurysms which are
partially within the cavernous sinus) or those which may not easily
hold a surgical clip such as calcified atherosclerotic aneurysms
GDC becomes the primary treatment option. GDC is also consider in
patients who wish to have treatment but desire not to have a craniotomy.
References:
- Guglielmi G, Vinuela F, Sepetka
I, et al. Electrothrombosis of saccular aneurysms via endovascular
approach. Part 1: Eletrochemical basis, technique and experimental
results. J Neurosurg, 75:1-7, 1991.
- Guglielmi G, Vinuela F, Dion J,
et al. Electrothrombosis of saccular aneurysms via endovascular
approach. Part 2: Preliminary clinical experience. J Neurosurg
75:8-14, 1990.
- Malisch TW, Guglielmi G, Vineula
F, Duckwiler G, Gobin YP, Martin NA, Frazee JG. Intracranial aneurysms
treated with the Guglielmi detachable coil: midterm clinical results
in a consecutive series of 100 patients, J Neurosurg 87:176-183
(1997).
|